GRI Bio (NASDAQ:GRI) Stock Price Down 2.8%

Shares of GRI Bio, Inc. (NASDAQ:GRIGet Free Report) were down 2.8% during mid-day trading on Tuesday . The company traded as low as 0.43 and last traded at 0.45. Approximately 143,300 shares changed hands during trading, a decline of 77% from the average daily volume of 616,372 shares. The stock had previously closed at 0.46.

GRI Bio Trading Down 2.8 %

The stock has a market capitalization of $1.43 million, a PE ratio of -0.01 and a beta of -1.77. The firm has a 50 day moving average of 0.74 and a two-hundred day moving average of 3.34.

About GRI Bio

(Get Free Report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

See Also

Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with's FREE daily email newsletter.